Alzamend Neuro

About Alzamend Neuro

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel treatments for Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). Their mission is to rapidly develop and market safe and effective treatments to aid over 43 million Americans suffering from these debilitating conditions.

Products & Services

AL001:A patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline, and salicylate, aimed at treating Alzheimer's, Bipolar Disorder, MDD, and PTSD.

ALZN002:A patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the patient's immunological system to combat Alzheimer's.

Specialties

Alzheimer's Disease Treatment Bipolar Disorder Treatment Major Depressive Disorder Treatment Post-Traumatic Stress Disorder Treatment Ionic Cocrystal Technology Cell-Based Therapeutic Vaccine

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2025-06-16 FD: 2025-06-16	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2024-05-10 FD: 2024-05-10	1 investors
3	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 25000000 MR: - FA: up to $25 million FAN: 25000000	D: 2024-05-10 FD: 2024-05-10	1 investors

Private Placement Latest

2025-06-16

$5.0M

1 investor (Pro only)

Private Placement 2024-05-10

$25.0M

Registered Direct Offering and Concurrent Private Placement 2024-05-10

$25.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Eric M. McDade

Co-Director of the DIAN Trials Unit and Clinical Trials Leadership at Washington University School of Medicine

T

Thomas M. Wisniewski

Director of NYU Langone's Pearl I. Barlow Center for Memory Evaluation and Treatment

T

Terri Hunter

20+ years Experience, Research and Technology Transfer and Partnerships

S

Stephan Jackman

Chief Executive Officer and Director

W

William B. Horne

Chairman of Alzamend, Chief Executive Officer of Ault Alliance, Inc.

H

Henry C.W. Nisser

Executive Vice President, General Counsel and Director

View 10 more team members with Pro

Unlock Full Team Directory

Recent News

Alzamend Neuro Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised